U.S. & U.K. payers want greater discounts on Orkambi

Both the state of New York and NHS England have requested that Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) provide a lower price for its cystic fibrosis drug Orkambi ivacaftor/lumacaftor, but the biotech is unlikely to do so -- at least at the level requested by New York’s Medicaid program.

On Thursday, the New York state Drug Utilization Review (DUR) board voted

Read the full 587 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers